➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Dow
Medtronic
Harvard Business School
Colorcon
Merck

Last Updated: August 2, 2021

DrugPatentWatch Database Preview

LAMIVUDINE AND ZIDOVUDINE Drug Patent Profile


Email this page to a colleague

« Back to Dashboard

When do Lamivudine And Zidovudine patents expire, and what generic alternatives are available?

Lamivudine And Zidovudine is a drug marketed by Anda Repository, Aurobindo Pharma Ltd, Cipla, Hetero Labs Ltd Iii, Hetero Labs Ltd V, Lupin Ltd, Macleods Pharms Ltd, Mylan, Mylan Labs Ltd, Pharmacare, Strides Pharma, and Teva Pharms. and is included in thirteen NDAs.

The generic ingredient in LAMIVUDINE AND ZIDOVUDINE is lamivudine; zidovudine. There are twenty-nine drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the lamivudine; zidovudine profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Lamivudine And Zidovudine

A generic version of LAMIVUDINE AND ZIDOVUDINE was approved as lamivudine; zidovudine by AUROBINDO PHARMA LTD on May 15th, 2012.

  Free Forever Trial

Summary for LAMIVUDINE AND ZIDOVUDINE
Drug patent expirations by year for LAMIVUDINE AND ZIDOVUDINE
Recent Clinical Trials for LAMIVUDINE AND ZIDOVUDINE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
University of Cape TownPhase 4
Infectious Diseases Institute, UgandaPhase 3
Médecins Sans Frontières, BelgiumPhase 4

See all LAMIVUDINE AND ZIDOVUDINE clinical trials

US Patents and Regulatory Information for LAMIVUDINE AND ZIDOVUDINE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Anda Repository LAMIVUDINE AND ZIDOVUDINE lamivudine; zidovudine TABLET;ORAL 206375-001 Apr 10, 2018 AB RX No No ⤷  Free Forever Trial ⤷  Free Forever Trial ⤷  Free Forever Trial
Lupin Ltd LAMIVUDINE AND ZIDOVUDINE lamivudine; zidovudine TABLET;ORAL 090246-001 May 15, 2012 AB RX No No ⤷  Free Forever Trial ⤷  Free Forever Trial ⤷  Free Forever Trial
Cipla LAMIVUDINE AND ZIDOVUDINE lamivudine; zidovudine TABLET;ORAL 077411-001 Sep 7, 2018 AB RX No No ⤷  Free Forever Trial ⤷  Free Forever Trial ⤷  Free Forever Trial
Strides Pharma LAMIVUDINE AND ZIDOVUDINE lamivudine; zidovudine TABLET;ORAL 079128-001 May 13, 2015 AB RX No No ⤷  Free Forever Trial ⤷  Free Forever Trial ⤷  Free Forever Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Dow
Medtronic
Harvard Business School
Colorcon
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.